These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34020338)

  • 1. Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development.
    S AH; Pujar GV; Sethu AK; Bhagyalalitha M; Singh M
    Eur J Med Chem; 2021 Oct; 221():113527. PubMed ID: 34020338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.
    Anasir MI; Ramanathan B; Poh CL
    Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Potential Inhibitors for Targets Involved in Dengue Fever.
    Shanmugam A; Ramakrishnan C; Velmurugan D; Gromiha MM
    Curr Top Med Chem; 2020; 20(19):1742-1760. PubMed ID: 32552652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Direct-Acting Antiviral Agent Targeting RNA Helicase via a Graphene Oxide Nanobiosensor.
    Kim J; Park SJ; Park J; Shin H; Jang YS; Woo JS; Min DH
    ACS Appl Mater Interfaces; 2021 Jun; 13(22):25715-25726. PubMed ID: 34036784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten years of dengue drug discovery: progress and prospects.
    Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
    Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An iminosugar with potent inhibition of dengue virus infection in vivo.
    Perry ST; Buck MD; Plummer EM; Penmasta RA; Batra H; Stavale EJ; Warfield KL; Dwek RA; Butters TD; Alonzi DS; Lada SM; King K; Klose B; Ramstedt U; Shresta S
    Antiviral Res; 2013 Apr; 98(1):35-43. PubMed ID: 23376501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides as Therapeutic Agents for Dengue Virus.
    Chew MF; Poh KS; Poh CL
    Int J Med Sci; 2017; 14(13):1342-1359. PubMed ID: 29200948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening.
    Barral K; Sallamand C; Petzold C; Coutard B; Collet A; Thillier Y; Zimmermann J; Vasseur JJ; Canard B; Rohayem J; Debart F; Decroly E
    Antiviral Res; 2013 Sep; 99(3):292-300. PubMed ID: 23769894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in antiviral drug development towards dengue virus.
    Troost B; Smit JM
    Curr Opin Virol; 2020 Aug; 43():9-21. PubMed ID: 32795907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity of ST081006 against the dengue virus.
    Lee JK; Chui JLM; Lee RCH; Kong HY; Chin WX; Chu JJH
    Antiviral Res; 2019 Nov; 171():104589. PubMed ID: 31421165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the mode of action of a potent dengue virus capsid inhibitor.
    Scaturro P; Trist IM; Paul D; Kumar A; Acosta EG; Byrd CM; Jordan R; Brancale A; Bartenschlager R
    J Virol; 2014 Oct; 88(19):11540-55. PubMed ID: 25056895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The search for nucleoside/nucleotide analog inhibitors of dengue virus.
    Chen YL; Yokokawa F; Shi PY
    Antiviral Res; 2015 Oct; 122():12-9. PubMed ID: 26241002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue Antiviral Development: A Continuing Journey.
    Low JG; Gatsinga R; Vasudevan SG; Sampath A
    Adv Exp Med Biol; 2018; 1062():319-332. PubMed ID: 29845542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach.
    Aarthy M; Singh SK
    Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and Function of the Non-Structural Protein of Dengue Virus and its Applications in Antiviral Therapy.
    Xie Q; Zhang B; Yu J; Wu Q; Yang F; Cao H; Zhao W
    Curr Top Med Chem; 2017; 17(3):371-380. PubMed ID: 27572085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for development of Dengue virus inhibitors.
    Noble CG; Chen YL; Dong H; Gu F; Lim SP; Schul W; Wang QY; Shi PY
    Antiviral Res; 2010 Mar; 85(3):450-62. PubMed ID: 20060421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Medicinal Chemistry of Dengue Virus.
    Behnam MA; Nitsche C; Boldescu V; Klein CD
    J Med Chem; 2016 Jun; 59(12):5622-49. PubMed ID: 26771861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus.
    Leal ES; Adler NS; Fernández GA; Gebhard LG; Battini L; Aucar MG; Videla M; Monge ME; Hernández de Los Ríos A; Acosta Dávila JA; Morell ML; Cordo SM; García CC; Gamarnik AV; Cavasotto CN; Bollini M
    Eur J Med Chem; 2019 Nov; 182():111628. PubMed ID: 31472473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
    Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
    Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity of lanatoside C against dengue virus infection.
    Cheung YY; Chen KC; Chen H; Seng EK; Chu JJ
    Antiviral Res; 2014 Nov; 111():93-9. PubMed ID: 25251726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.